Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

0.1518
+0.00281.88%
Post-market: 0.15220.0004+0.26%19:53 EDT
Volume:671.79K
Turnover:101.65K
Market Cap:3.05M
PE:-0.08
High:0.1554
Open:0.1519
Low:0.1470
Close:0.1490
52wk High:3.42
52wk Low:0.1289
Shares:20.12M
Float Shares:19.98M
Volume Ratio:0.04
T/O Rate:3.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8267
EPS(LYR):-2.0700
ROE:-8585.26%
ROA:-56.19%
PB:-0.62
PE(LYR):-0.07

Loading ...

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06

Vivos Therapeutics Agrees Debt for Equity Deal With Streeterville Capital

MT Newswires Live
·
Jun 05

Vivos Therapeutics agrees to exchange up to $4.5 million Streeterville debt into preferred, common stock

Reuters
·
Jun 05

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing

THOMSON REUTERS
·
Jun 05

Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Dow Jones
·
Jun 05

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 04

Vivos Therapeutics Earnings Call: Growth Meets Cash Strain

TIPRANKS
·
May 22

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

TIPRANKS
·
May 21

Vivos Therapeutics Q1 revenue jumps, driven by SCN acquisition

Reuters
·
May 21

Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Benzinga Earnings
·
May 21

Vivos Therapeutics Q1 FY26 net loss more than doubles to $7.8 million; revenue rises 70% to $5.1 million

Reuters
·
May 21

BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million

Reuters
·
May 21

Vivos Therapeutics Q1 Gross Profit USD 3.059 Million

THOMSON REUTERS
·
May 21

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
May 21

Vivos Therapeutics Delays Quarterly Filing

TIPRANKS
·
May 16

Vivos Therapeutics delays Q1 10-Q filing, seeks SEC extension

Reuters
·
May 16

Vivos Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 12

Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges

TIPRANKS
·
Apr 23

Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule

Reuters
·
Apr 23

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Apr 22